Physician profile
Jonathan Pankow
NPI 1962817783
$3,061.54
in general payments reported to CMS, 2019-2025
25 companies · $662 in 2025
The $662 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $125 · 2021: $315 · 2022: $535 · 2023: $501 · 2024: $923 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,086.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $632.10 | 2020-2025 | Farxiga |
| Travere Therapeutics, INC. | $300.96 | 2024-2025 | Filspari |
| Vifor Pharma, INC. | $257.97 | 2021-2025 | Veltassa |
| Amgen INC. | $221.14 | 2022-2025 | Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $213.55 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $171.00 | 2023-2024 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $153.33 | 2025 | |
| Horizon Therapeutics Plc | $151.29 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $130.73 | 2021-2024 | Rayaldee |
| Aurinia Pharma U.S., INC. | $121.68 | 2022-2024 | Lupkynis |
| Medtronic, INC. | $111.05 | 2023 | Ellipsys Vascular Access System |
| Mallinckrodt Hospital Products INC. | $94.05 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.37 | 2021-2022 | |
| Fresenius USA Marketing, INC. | $78.16 | 2022-2024 | Velphoro |
| Otsuka America Pharmaceutical, INC. | $73.89 | 2021-2024 | Jynarque |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $58.17 | 2021-2022 | |
| Scpharmaceuticals INC. | $40.89 | 2025 | |
| Apellis Pharmaceuticals, INC. | $34.35 | 2025 | Empaveli |
| Recor Medical INC | $27.70 | 2025 | Paradise Ultrasound Renal Denervation System |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.72 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.48 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $19.26 | 2021 | |
| Genentech USA, INC. | $16.37 | 2025 | |
| Shield Therapeutics INC | $13.77 | 2022 | |
| Pfizer INC. | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Pankow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.